Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Formule :C58H72ClFN12O8SCouleur et forme :SolidMasse moléculaire :1151.78MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Formule :C20H16F6N4O2SCouleur et forme :SolidMasse moléculaire :490.422Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Formule :C23H21ClN8O2S2Couleur et forme :SolidMasse moléculaire :541.048Caffeic acid-pYEEIE
CAS :<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Formule :C39H50N5O19PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :923.82SJ1008030
CAS :<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formule :C42H43N13O7SCouleur et forme :SolidMasse moléculaire :873.94Syk-IN-4
<p>Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.</p>Couleur et forme :SolidDSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Couleur et forme :Odour SolidFLT3-IN-29
<p>FLT3-IN-29 (Compound MY-10) is an FLT3 inhibitor with IC50 values of 6.5 nM and 10.3 nM for FLT3-ITD and FLT3-D835Y mutants, respectively. It induces cell cycle arrest at the G0/G1 phase and effectively triggers apoptosis (Apoptosis). Additionally, FLT3-IN-29 reduces reactive oxygen species (ROS) and mitochondrial membrane potential (MMP), displaying anti-leukemic properties.</p>Formule :C25H30N6O2Couleur et forme :SolidMasse moléculaire :446.545BMS-599626 2HCL(714971-09-2 Free base)
CAS :<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Formule :C27H29Cl2FN8O3Degré de pureté :99.11%Couleur et forme :Odour SolidMasse moléculaire :603.47JAK1/TYK2-IN-1
CAS :<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401JAK3-IN-14
CAS :<p>JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.</p>Formule :C18H13N3ODegré de pureté :98.29%Couleur et forme :SoildMasse moléculaire :287.32Emodic acid
CAS :<p>Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.</p>Formule :C15H8O7Couleur et forme :SolidMasse moléculaire :300.222PTD10
CAS :<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Formule :C49H51N11O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :922EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Formule :C22H16ClFN4O2Masse moléculaire :422.09458EGFR-IN-22
CAS :<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Formule :C38H47BrFN10O2PCouleur et forme :SolidMasse moléculaire :805.72Angiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Couleur et forme :Odour SolidEGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Formule :C68H84N12O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1213.47Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Degré de pureté :98%Couleur et forme :Odour SolidMET/PDGFRA-IN-1
<p>MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.</p>Formule :C26H23N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :449.51KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Formule :C26H18F3N5O2Couleur et forme :SolidMasse moléculaire :489.449PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Formule :C46H48N10O6Couleur et forme :SolidMasse moléculaire :836.94Bemarituzumab
CAS :<p>Bemarituzumab: humanized IgG1 antibody inhibits FGFR2b, may be used in cancer research.</p>Degré de pureté :SDS-PAGE:95% SEC-HPLC:99.99%Couleur et forme :LiquidMasse moléculaire :144 kDaAS2553627
CAS :<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formule :C18H19N5OCouleur et forme :SolidMasse moléculaire :321.38INCB-000928
CAS :<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Formule :C30H38N4O3Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :502.65EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Formule :C22H18FN3O3Masse moléculaire :391.13322HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Couleur et forme :Odour SolidAG-1478 hydrochloride
CAS :<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Formule :C16H15Cl2N3O2Couleur et forme :SolidMasse moléculaire :352.21FGFR2 degrader 1
<p>FGFR2 degrader1 (compound 28E) is a selective PROTACS degrader of FGFR2, with a DC50 of 0.645 nM. FGFR2 plays a significant role in cancer research.</p>Formule :C40H39Cl2N9O6Masse moléculaire :811.24004Sorafenib-d4
CAS :<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Formule :C21H16ClF3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.85PROTAC TYK2 degradation agent1
CAS :<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formule :C55H69N13O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1056.28MPT0B390
CAS :<p>MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.</p>Formule :C17H17N3O5SDegré de pureté :99.4%Couleur et forme :SolidMasse moléculaire :375.4cep-5214
CAS :<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Formule :C28H28N2O3Couleur et forme :SolidMasse moléculaire :440.53EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Formule :C49H53ClFN5O5Couleur et forme :SolidMasse moléculaire :846.43PACAP-38 (31-38), human, mouse, rat
CAS :<p>PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production</p>Formule :C47H83N17O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1062.27EGFR/HER2/DHFR-IN-3
<p>EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.</p>Degré de pureté :98%Couleur et forme :Odour SolidPROTAC EGFR degrader 4
CAS :<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Formule :C55H70N12O4SCouleur et forme :SolidMasse moléculaire :995.29DB1113
CAS :<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Formule :C59H68F3N13O6SCouleur et forme :SolidMasse moléculaire :1144.31VSLRGDTRG acetate
<p>VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.</p>Couleur et forme :Odour SolidSNIPER(ABL)-033
CAS :<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Formule :C61H73F3N10O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1211.42PROTAC FLT3/CDK9 degrader-1
<p>Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.</p>Formule :C48H62N12O7Couleur et forme :SolidMasse moléculaire :919.08ALK-IN-9
CAS :<p>ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.</p>Formule :C20H21FN6O3Couleur et forme :SolidMasse moléculaire :412.425Sozinibercept
CAS :<p>Sozinibercept (OPT 302; VGX-300), a VEGFR-3 inhibitor, blocks VEGF-C/D to curb angiogenesis and vascular leakage, and treats rat diabetic retinal edema.</p>Couleur et forme :LiquidGefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Formule :C22H24ClFN4O41·5HClCouleur et forme :SolidMasse moléculaire :517.59BTK-IN-5
CAS :<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formule :C23H32N4O5Couleur et forme :SolidMasse moléculaire :444.532SNIPER(ABL)-049
<p>SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,</p>Formule :C52H66N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :959.14M4K2234
CAS :<p>M4K2234 (26b) inhibits ALK2/ALK5 (IC50: 5/2144 nM), used as a probe for ALK1/2 kinases in cancer research.</p>Formule :C27H31FN4O2Couleur et forme :SolidMasse moléculaire :462.56PROTAC BTK Degrader-6
CAS :<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formule :C45H47N11O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :837.92TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formule :C23H21FN4O2Couleur et forme :SolidMasse moléculaire :404.16485PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Formule :C46H50F3N13O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :969.97SI-2
CAS :<p>SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.</p>Formule :C15H15N5Degré de pureté :98.4%Couleur et forme :SolidMasse moléculaire :265.31VEGFR-2-IN-64
<p>VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.</p>Formule :C72H123N9O6Couleur et forme :SolidMasse moléculaire :1210.87-Hydroxyneolamellarin A
CAS :<p>7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.</p>Formule :C24H19NO5Couleur et forme :SolidMasse moléculaire :401.41U3-1565
<p>U3-1565 (Anti-HB-EGF antibody) is an antibody targeting HB-EGF with potential anti-tumor activity, used in the study of advanced solid tumors.</p>Couleur et forme :LiquidMasse moléculaire :144.82 kDa (Predicted)Nezutatug
CAS :<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Degré de pureté :98%Couleur et forme :LiquidEfimosfermin alfa
<p>Efimosfermin alfa is a humanized antibody targeting FGFR1.</p>Couleur et forme :Odour LiquidSJ10542
CAS :<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formule :C41H46N12O5SCouleur et forme :SolidMasse moléculaire :818.95Tomuzotuximab
CAS :<p>Tomuzotuximab: fully human, glycoengineered IgG1 anti-EGFR monoclonal antibody with anticancer properties.</p>Couleur et forme :LiquidIstiratumab
CAS :<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Couleur et forme :LiquidPROTAC EGFR degrader 5
CAS :<p>PROTAC EGFR degrader 5 effectively breaks down EGFR Del19 in HCC827 cells at 34.8 nM, inducing apoptosis and G1 arrest.</p>Formule :C57H72FN13O5SCouleur et forme :SolidMasse moléculaire :1070.33FAK PROTAC B5
CAS :<p>FAK PROTAC B5: a degrader with 14.9 nM IC50, strong degradation, anti-growth, good plasma stability, and fair permeability.</p>Formule :C41H43ClN10O7Couleur et forme :SolidMasse moléculaire :823.3HER2-IN-14
CAS :<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Formule :C26H23ClF2N8O3Couleur et forme :SolidMasse moléculaire :568.96Coprelotamab
CAS :<p>Coprelotamab (GB-221) is an IgG-κ monoclonal antibody that targets EGFR2, frequently produced in CHO DG44 (Chinese Hamster Ovary) cells [1].</p>Degré de pureté :98%Couleur et forme :LiquidFLT3-IN-20
<p>FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.</p>Formule :C28H33N7O2SCouleur et forme :SolidMasse moléculaire :531.67VEGFR-2-IN-36
<p>VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstrated</p>Formule :C24H23N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :489.48EGFR-IN-15
CAS :<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Formule :C24H25BrN6O2Couleur et forme :SolidMasse moléculaire :509.408Anticancer agent 133
<p>Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy.</p>Formule :C24H19Cl3N5ORhDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :602.71AST5902
CAS :<p>AST5902 is the active metabolite of Alflutinib.</p>Formule :C27H29F3N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :554.57JAK 3 inhibitor IV
CAS :<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Formule :C16H19NODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :241.33Os30
<p>Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and</p>Degré de pureté :98%Couleur et forme :Odour SolidZeteletinib hemiadipate
CAS :<p>Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.</p>Formule :C56H56F6N8O12Couleur et forme :SolidMasse moléculaire :1147.098GSK143
CAS :<p>GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.</p>Formule :C17H22N6O2Couleur et forme :SolidMasse moléculaire :342.403Caxmotabart
<p>Caxmotabart is a humanized IgG1κ antibody targeting ERBB2, with HumanIgG1kappa, Isotype Control as its corresponding isotype control.</p>Couleur et forme :Odour LiquidBV02
CAS :<p>BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.</p>Formule :C20H15N3O5Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :377.35SNIPER(ABL)-039
CAS :<p>SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of</p>Formule :C54H68ClN11O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1114.77MHES0488A
<p>MHES0488A is a selective humanized antibody targeting HER2, with a KD value of 0.8 nM. It constitutes the antibody portion of DHES0815A. Upon cellular internalization, MHES0488A is transported to lysosomes, releasing PBD-monoamide into the nucleus, where it alkylates DNA, inducing DNA damage and apoptosis. It shows potential for research in cancers such as HER2-positive breast cancer and gastric cancer.</p>Couleur et forme :Odour LiquidRR-src
CAS :<p>Tyrosine kinase substrate peptide</p>Formule :C64H106N22O21Degré de pureté :98%Couleur et forme :Lyophilized PowderMasse moléculaire :1519.66FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Couleur et forme :Odour SolidSJF 1521
CAS :<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formule :C57H61ClFN7O9SDegré de pureté :99.20%Couleur et forme :SolidMasse moléculaire :1074.65Tyrosinase-IN-16
CAS :<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Formule :C8H6BrN3SDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :256.12SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Formule :C67H82F3N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1274.5SC209
CAS :<p>SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.</p>Formule :C27H44N4O4Couleur et forme :SolidMasse moléculaire :488.66CNX-500
CAS :<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Formule :C48H68N10O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :961.18BCR-ABL-IN-3
CAS :<p>BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.</p>Formule :C20H17ClF2N4O3SCouleur et forme :SolidMasse moléculaire :466.89SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Formule :C25H29F3N4O3Couleur et forme :SolidMasse moléculaire :490.52JAK-IN-15
CAS :<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formule :C22H23FN4O3SCouleur et forme :SolidMasse moléculaire :442.51VEGFR2/HDAC1-IN-1
<p>VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.</p>Degré de pureté :98%Couleur et forme :Odour SolidTrastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Couleur et forme :Odour LiquidTL13-112
CAS :<p>TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).</p>Formule :C49H60ClN9O10SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1002.57EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Formule :C27H37FN8O2Couleur et forme :SolidMasse moléculaire :524.633LC-MB12
CAS :<p>LC-MB12 is a PROTAC FGFR2 compound that degrades FGFR2 and can be used to study gastric cancer.</p>Formule :C43H44Cl2N10O8Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :899.78AZ12672857
CAS :<p>AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.</p>Formule :C26H30N8O2Degré de pureté :98.99%Couleur et forme :SolidMasse moléculaire :486.57PROTAC BTK Degrader-1
CAS :<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formule :C43H43N9O4Couleur et forme :SolidMasse moléculaire :749.86K882
<p>K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.</p>Formule :C18H16N2O2Couleur et forme :SolidMasse moléculaire :292.33VEGFR/PARP-IN-1
<p>VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.</p>Formule :C29H27N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.58Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Formule :C19H15N5O2SCouleur et forme :SolidMasse moléculaire :377.42FAK-IN-24
CAS :<p>FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.</p>Formule :C39H45Cl2F3N8O3Couleur et forme :SolidMasse moléculaire :801.728FLT3/VEGFR2-IN-1
<p>FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.</p>Formule :C29H35N7O5Couleur et forme :SolidMasse moléculaire :561.63AXL/Angiokinase-IN-1
<p>AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.</p>Formule :C31H34ClN5O2Couleur et forme :SolidMasse moléculaire :544.09LC-SF-14
<p>LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.</p>Formule :C44H50Cl3N13O5SCouleur et forme :SolidMasse moléculaire :977.28442SJ988497
CAS :<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74Efruxifermin
CAS :<p>Efruxifermin, a modified FGF21 with IgG1 Fc, has increased stability and affinity. Used in non-alcoholic steatohepatitis research.</p>Couleur et forme :LiquidEGFR-IN-86
<p>EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell</p>Formule :C20H21N7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :423.49Lyso-Monosialoganglioside GM3
CAS :<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formule :C41H74N2O20Couleur et forme :SolidMasse moléculaire :915.028AKN-028
CAS :<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formule :C17H14N6Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :302.33Ibrutinib dimer
CAS :<p>Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).</p>Formule :C50H48N12O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :880.99JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Formule :C33H30F4N4O5SCouleur et forme :SolidMasse moléculaire :670.67EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formule :C22H17F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.39PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Formule :C43H40N10O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :792.84HER2-IN-13
CAS :<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Formule :C26H23ClF2N8O3Couleur et forme :SolidMasse moléculaire :568.96DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Couleur et forme :Odour SolidAD57
CAS :<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formule :C22H20F3N7ODegré de pureté :99.05%Couleur et forme :SoildMasse moléculaire :455.44SA-VA
<p>SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.</p>Formule :C50H53ClF3N11O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1044.54PROTAC FAK degrader 1
CAS :<p>PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).</p>Formule :C47H56F3N9O8S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :996.13FAK-IN-27
<p>FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).</p>Formule :C32H28ClN5O6Couleur et forme :SolidMasse moléculaire :613.17281TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Couleur et forme :Odour SolidBTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Couleur et forme :Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98DSPE-PEG2000-A7R
<p>DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.</p>Couleur et forme :Odour SolidMP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Couleur et forme :Odour LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formule :C20H17Cl2N3O3Couleur et forme :SolidMasse moléculaire :418.273SA-PA
<p>SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cells</p>Formule :C40H32ClF3N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :873.19EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Formule :C50H55ClFN5O5Couleur et forme :SolidMasse moléculaire :860.45ALK-IN-13
CAS :<p>ALK-IN-13 is an ALK inhibitor.</p>Formule :C29H39ClN7O2PCouleur et forme :SolidMasse moléculaire :584.1Axltide
CAS :<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77SNIPER(ABL)-019
<p>SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a</p>Formule :C60H77ClN12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1177.85DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Couleur et forme :Odour Solid(R)-3-Hydroxy Midostaurin
CAS :<p>(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.</p>Formule :C35H30N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.648BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formule :C28H29FN6O2SCouleur et forme :SolidMasse moléculaire :532.63Duligotuzumab
CAS :<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Degré de pureté :95% - 95%Couleur et forme :LiquiddALK-3
<p>dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.</p>Formule :C39H45ClN7O5PCouleur et forme :SolidMasse moléculaire :758.245PROTAC BTK Degrader-2
CAS :<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Formule :C47H54F2N8O13Couleur et forme :SolidMasse moléculaire :976.97Syk Inhibitor II hydrochloride
CAS :<p>Syk signaling is key in lupus. Syk inhibitors reduce inflammation and sepsis severity in FcgRIIb-/- mice, lowering cytokines and organ damage.</p>Formule :C14H16ClF3N6ODegré de pureté :99.05%Couleur et forme :SolidMasse moléculaire :376.77Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formule :C33H34N4O3Couleur et forme :SolidMasse moléculaire :534.648Si5-N14
CAS :<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Formule :C78H160N6O5Si2Couleur et forme :SolidMasse moléculaire :1318.31DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Couleur et forme :LiquidEGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formule :C20H17FN6O2S2Couleur et forme :SolidMasse moléculaire :456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Formule :C22H22FN5O2Couleur et forme :SolidMasse moléculaire :407.44HDS 029
CAS :<p>HDS 029 has a wide range of applications in life science related research.</p>Formule :C17H11ClFN5OCouleur et forme :SolidMasse moléculaire :355.76Secretin, canine
CAS :<p>Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.</p>Formule :C131H222N44O41Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :3069.43EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Formule :C17H15N7O5SCouleur et forme :SolidMasse moléculaire :429.41EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Couleur et forme :Odour SolidFGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44MY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Formule :C25H29ClN8O2Couleur et forme :SolidMasse moléculaire :509Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Couleur et forme :Odour LiquidMulti-kinase-IN-4
<p>Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.</p>Formule :C21H20ClFN2OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :402.91Scr-IN-1
<p>Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.</p>Formule :C26H16ClF3N2O3Couleur et forme :SolidMasse moléculaire :496.87MS9427
CAS :<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formule :C48H58ClFN8O12Couleur et forme :SolidMasse moléculaire :993.47SIAIS164018 hydrochloride
<p>SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R.</p>Formule :C43H49Cl2N10O7PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.79SPP-037
<p>SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.</p>Formule :C36H50ClN3O9SCouleur et forme :SolidMasse moléculaire :735.29563SNIPER(ABL)-044
<p>SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a</p>Formule :C51H64F3N9O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.17EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Formule :C22H16N4OSCouleur et forme :SolidMasse moléculaire :384.45CPD-1224
CAS :<p>CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.</p>Formule :C43H47ClN8O7SCouleur et forme :SolidMasse moléculaire :855.4Multi-kinase-IN-6
<p>Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.</p>Degré de pureté :98%Couleur et forme :Odour SolidFGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Formule :C36H42N12O6Couleur et forme :SolidMasse moléculaire :738.335033-Methylthienyl-carbonyl-JNJ-7706621
CAS :<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.432-Keto Crizotinib
CAS :<p>2-Keto Crizotinib is an active lactam metabolite of crizotinib.</p>Formule :C21H20Cl2FN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.32Amuvatinib hydrochloride
CAS :<p>Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.</p>Formule :C23H22ClN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.97Coumermycin A1
CAS :<p>Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.</p>Formule :C55H59N5O20Couleur et forme :SolidMasse moléculaire :1110.092Verucopeptin
CAS :<p>Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.</p>Formule :C43H73N7O13Couleur et forme :SolidMasse moléculaire :896.08TL13-12
CAS :<p>TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).</p>Formule :C45H53ClN10O10SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :961.49YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Couleur et forme :Odour LiquidFLT3-IN-28
<p>FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor properties. It selectively targets cancer cells with FLT3 internal tandem duplication (ITD) mutations, demonstrating IC50 values of 85, 290, 130, 65, and 220 nM against BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines, respectively. These lines include acute myeloid leukemia (AML) cells harboring FLT3-ITD mutations such as MV4-11 and MOLM-13/14. The compound also reduces phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells, leading to cell cycle arrest and apoptosis. With an oral bioavailability of 19.2% in SD rats, FLT3-IN-28 extends survival in a dose-dependent manner in MOLM-13 xenografted NSG mouse models. It holds promise for research in FLT3-ITD-related cancer studies.</p>Formule :C23H19FN8O4Couleur et forme :SolidMasse moléculaire :490.447TL13-110
CAS :<p>Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).</p>Formule :C49H62ClN9O9SCouleur et forme :SolidMasse moléculaire :988.59Simotinib hydrochloride
CAS :<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Formule :C25H27Cl2FN4O4Couleur et forme :SolidMasse moléculaire :537.41PROTAC EGFR degrader 8
CAS :<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formule :C40H46ClN11O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :796.32DSPE-PEG1000-A7R
<p>DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Couleur et forme :Odour SolidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Couleur et forme :Odour SolidWu-5
CAS :<p>Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.</p>Formule :C15H13NO7SDegré de pureté :99.29%Couleur et forme :SoildMasse moléculaire :351.33MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Formule :C20H14ClFN6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :392.82BTK inhibitor 19
CAS :<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Formule :C25H24F3N7O3Couleur et forme :SolidMasse moléculaire :527.508EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formule :C23H32BrN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.51PST3.1a
CAS :<p>PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).</p>Formule :C32H33O6PCouleur et forme :SolidMasse moléculaire :544.57GBD-9
CAS :<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Formule :C44H47N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.9ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formule :C47H53BrCl2N10O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1052.86hCA/VEGFR-2-IN-3
<p>hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.</p>Formule :C24H28N6O6SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.58Syk Kinase Peptide Substrate, Biotin labeled
<p>The compound, Biotin-labeled Syk Kinase Peptide Substrate, is a peptide substrate of Syk kinase that is labeled with biotin.</p>Formule :C76H108N18O24S1Couleur et forme :SolidMasse moléculaire :1689.9PROTAC EGFR degrader 3
CAS :<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Formule :C60H77N13O5SCouleur et forme :SolidMasse moléculaire :1092.4Varlitinib Tosylate
CAS :<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formule :C36H35ClN6O8S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :811.34Lyn peptide inhibitor
CAS :<p>Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.</p>Formule :C115H184N30O24Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2370.91PROTAC FGFR1 degrader-1
<p>PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.</p>Formule :C46H54N8O8Couleur et forme :SolidMasse moléculaire :846.97Tephrosin
CAS :<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Formule :C23H22O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.42PROTAC BCR-ABL1 ligand 1
CAS :<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formule :C17H12F3N3O2Couleur et forme :SoildMasse moléculaire :347.29COVA208
<p>COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.</p>Couleur et forme :Odour LiquidhCA/VEGFR-2-IN-4
<p>hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/</p>Formule :C22H23FN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.52PACAP-38 (31-38), human, mouse, rat TFA
<p>PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.</p>Formule :C49H84F3N17O13Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1176.29VnP-16
<p>VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activates</p>Formule :C82H112N20O17Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1649.89EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Couleur et forme :Odour LiquidEGFR/BRAFV600E-IN-3
<p>EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.</p>Formule :C25H18N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :422.44Antifibrotic agent 1
<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>Formule :C27H23ClN6O2Couleur et forme :SolidMasse moléculaire :498.1571MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Formule :C50H59ClF4N8O14Couleur et forme :SolidMasse moléculaire :1107.5IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Couleur et forme :Odour LiquidSJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96IMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Couleur et forme :Odour LiquidE7090
CAS :<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Formule :C32H37N5O6Couleur et forme :SolidMasse moléculaire :587.67Abl Cytosolic Substrate
CAS :<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Formule :C64H101N15O16Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1336.58ABP-102
<p>ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.</p>Couleur et forme :Odour LiquidJAK/HDAC-IN-2
<p>JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.</p>Formule :C28H38N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :570.7
